Drug Companies Ditch Animal Testing for Human Models

The future of drug testing doesn't involve animals anymore. Major pharmaceutical companies are racing to adopt human-based models that scientists say work better at predicting how medicines will actually affect people.

At a recent conference in London, Merck KGaA announced plans to replace most of its animal testing with newer preclinical models over the next 10 years. The shift comes as global regulators encourage drug makers to use "human-centric" approaches that better predict how treatments will perform in real patients.

These new approach methodologies, called NAMs, include organs-on-a-chip, computational simulations, and organoids (miniature lab-grown organs). Scientists are particularly excited about using fresh human tumors with intact microenvironments, which closely mirror what happens in actual patients.

David Apelion, CEO of British biotech company Theolytics, uses this approach to develop cancer treatments. His team tests therapies on real human tumor tissue instead of mice. "That kind of relevant component in preclinical selection will reduce the failure rate dramatically," he explained.

The technology is already making the biggest impact in oncology and cardiovascular disease research. By testing on human tissue from the start, drug developers can identify promising treatments faster and avoid expensive failures later in clinical trials.

The Ripple Effect

This transformation goes beyond just sparing animals. Human-based models are helping researchers ask better questions and make smarter decisions earlier in the drug development process.

Experts caution that success depends on thoughtful implementation. Chris Floyd, head of neuroscience at pharmaceutical consultancy tranScrip, warns against adopting fancy new tools without clear purpose. "We must be careful not to swap an expensive model we understand for an expensive one we don't," he said.

The key is designing experiments around specific questions that will actually move drug development forward. With technology advancing rapidly, scientists can now generate massive amounts of information from a single experiment, but only if they know what they're looking for.

Orr Inbar, CEO of clinical trial simulation company QuantHealth, sees the shift as a win for everyone. Better models mean fewer failed drugs, lower development costs, and ultimately more effective treatments reaching patients who need them.

The pharmaceutical industry is proving that doing the right thing for animals can also mean doing the right thing for human health.